Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with
 spike protein D178H and membrane protein V70L mutations

Lishuang Shen¹, Jennifer Dien Bard¹, Timothy J. Triche¹, Alexander R. Judkins¹, Jaclyn A.
Biegel¹, Xiaowu Gai¹

5

- ⁶ ¹Children's Hospital Los Angles, Department of Pathology and Laboratory Medicine,
- 7 Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.
- 8
- 9 Correspondence to:

10

- 11 Xiaowu Gai, PhD
- 12 Center for Personalized Medicine
- 13 Division of Genomic Medicine
- 14 Department of Pathology and Laboratory Medicine
- 15 4650 Sunset Blvd., Mailstop #173
- 16 Los Angeles, CA 90027
- 17 Phone: (323) 644-8506
- 18 Email: <u>xgai@chla.usc.edu</u>

20 Abstract

The SARS-CoV-2 B.1.1.7 lineage is highly infectious and as of April 2021 accounted for 92% of 21 COVID-19 cases in Europe and 59% of COVID-19 cases in the U.S. It is defined by the N501Y 22 mutation in the receptor binding domain (RBD) of the Spike (S) protein, and a few other 23 24 mutations. These include two mutations in the N terminal domain (NTD) of the S protein, HV69-70del and Y144del (also known as Y145del due to the presence of tyrosine at both positions). 25 26 We recently identified several emerging SARS-CoV-2 variants of concerns, characterized by 27 Membrane (M) protein mutations, including I82T and V70L. We now identify a sub-lineage of B.1.1.7 that emerged through sequential acquisitions of M:V70L in November 2020 followed by 28 29 a novel S:D178H mutation first observed in early February 2021. The percentage of B.1.1.7 30 isolates in the U.S. that belong to this sub-lineage increased from 0.15% in February 2021 to 1.8% in April 2021. To date this sub-lineage appears to be U.S.-specific with reported cases in 31 31 states, including Hawaii. As of April 2021 it constituted 36.8% of all B.1.1.7 isolates in 32 33 Washington. Phylogenetic analysis and transmission inference with Nextstrain suggests this sub-34 lineage likely originated in either California or Washington. Structural analysis revealed that the 35 S:D178H mutation is in the NTD of the S protein and close to two other signature mutations of 36 B.1.1.7, HV69-70del and Y144del. It is surface exposed and may alter NTD tertiary 37 configuration or accessibility, and thus has the potential to affect neutralization by NTD directed antibodies. 38

39 Keywords:

40 SARS-CoV-2, D178H, V70L, B.1.1.7 lineage, COVID-19

41 Introduction

B.1.1.7 emerged in the UK and was the first major SARS-CoV-2 variant of concern (VOC) that 42 43 is both more transmissible and apparently more virulent (1). It now accounts for 50-90% of the 44 COVID-19 cases in U.S. and Europe. The Spike (S) protein N501Y mutation in the receptor-45 binding domain (RBD) confers higher binding affinity of the S protein for ACE2, while the other 46 two deletions, HV69-70del and Y144del in the N-terminal domain (NTD) may also play a role in ACE2 receptor binding or neutralizing antibody escape (2). With millions of new B.1.1.7 cases 47 48 in recent months, there is a very high probability of continuous acquisitions of new mutations, 49 some of which may result in the emergence of new and even more infectious sub-lineages of B.1.1.7. While these new mutations may not be significantly deleterious by themselves, but when 50 they appear in the context of other mutations within this VOC the result may be a more 51 52 transmissible or pathogenic virus. This calls for rigorous genomic surveillance for newly 53 acquired mutations in previously reported VOCs, including but not limited to B.1.1.7 and 54 B.1.351.

Using the Children's Hospital Los Angeles (CHLA) COVID-19 Analysis Research Database (CARD) (3), and viral sequences submitted to GISAID and NCBI GenBank, we have routinely performed genomic epidemiology and genomic surveillance studies of local, national and international databases (4-9). This allowed us to identify a new VOC (B.1.575) with a signature mutation I82T in the M gene (7). In the same study, we identified multiple other M mutations including V70L that are currently being encountered with significantly increased frequency. We

61 have identified the M:V70L mutation in multiple SARS-CoV-2 lineages but primarily in the 62 B.1.1.7 lineage. The B.1.1.7-M:V70L sub-lineage has been circulating at consistently moderate prevalence since November 2020. Through continuous genomic surveillance we identified the 63 64 subsequent acquisition of yet another Spike mutation, D178H, within this lineage. This new B.1.1.7 sub-lineage, carrying both M:V70L and S:D178H mutations, appeared in February 2021 65 but by April 2021 quickly increased to account for 36.8% and 1.8% of all reported B.1.1.7 66 genomes in Washington and the U.S., respectively, This B.1.1.7-M:V70L-S:D178H sub-lineage 67 is currently exclusive to the U.S. as of May 8, 2021, and had been detected in 31 states, with the 68 majority of cases found in Washington, California and Ohio. Here, we report its detection, 69 70 characterization, transmission, and evolution.

71 Materials and methods

72 Ethics approval.

73 Study design conducted at Children's Hospital Los Angeles was approved by the Institutional 74 Proview Reard under IPR CHLA 16 00420

74 Review Board under IRB CHLA-16-00429.

75 SARS-CoV-2 whole genome sequencing

76 Whole genome sequencing of the 2900 samples previously confirmed at Children's Hospital Los

77 Angeles to be positive for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-

78 PCR) was performed as previously described (5).

79 SARS-CoV-2 sequence and variant analysis, and emerging variant monitoring

Full-length SARS-CoV-2 sequences had been periodically downloaded from GISAID (10, 11) and NCBI GenBank. They were combined with SARS-CoV-2 sequences from CHLA patients, annotated, and curated using a suite of bioinformatics tools, CHLA-CARD, as previously described (3). A custom Surging Mutation Monitor (SMM) standardized and integrated the viral genome and demographic data, in order to identify the trend of surging mutations and lineages across state and country levels. The current study was based on the 1.33 million global viral genomes that were available on May 1st, 2021.

87 **Phylogenetic analysis**

88 Phylogenetic analysis was conducted using the NextStrain phylogenetic pipeline (version 3.0.1)

- 89 (https://nextstrain.org/). Mafft (v7.4) was used in multiple sequence alignment (12), IQ-Tree
- 90 (multicore version 2.1.1 COVID-edition) and TreeTime version 0.7.6 were used to infer and
- 91 time-resolve evolutionary trees, and reconstruct ancestral sequences and mutations (13, 14).
- 92 Phylogenetic analysis.

93 **Protein structure prediction**

- 94 Structural predictions of mutant Spike proteins were carried out against the wild type protein
- 95 PDB qhd43416 (https://zhanglab.ccmb.med.umich.edu/COVID-19/) using Missense3D service
- 96 hosted online by the Imperial College London (http://www.sbg.bio.ic.ac.uk/~missense3d/) (15).

97 CoV3D was used as the Spike Protein Mutation Viewer for the multiple mutations in B.1.1.7

98 (https://cov3d.ibbr.umd.edu/MutViewer/QTY83983).

99 **Results**

100 Identification of a rapidly emerging B.1.1.7 sub-lineage

We evaluated 1,333,679 SARS-CoV-2 viral genomes available on May 1st, 2021, including 101 2,900 from our own institution and the rest from GISAID and NCBI GenBank. We searched for 102 SARS-CoV-2 mutations with significantly higher prevalence rate in both the U.S. and globally. 103 Candidate mutations were further partitioned by pangolin lineage to identify emerging mutations 104 in the context of a specific lineage, such as B.1.1.7 or B.1.351. We focused initially on the M 105 mutations that we previously identified, including V70L, that were spiking near the end of 2020 106 (7). Overall the percentage of isolates that carried the M:V70L mutation had been relatively 107 stable in the U.S. and globally with a gradual month to month increase (**Table 1**). In the vast 108 majority of cases, the M:V70L mutation occurred on the B.1.1.7 lineage. While the percentage of 109 B.1.1.7 isolates with the V70L mutation remained relatively stable across the world, the 110 percentage fluctuated significantly in the U.S., attributable largely to the initial small number of 111 B.1.1.7 cases in the U.S. 112

- We identified the acquisition of another S mutation, D178H, in this B.1.1.7 sub-lineage (**Figure 1, Table 2**), which was estimated to have occurred on January 23, 2021. By April, the prevalence of SARS-CoV-2 isolates carrying the S:D178H mutation increased to 1.05% nationally and as high as 14.77% in Washington. When we examined the prevalence of S:D178H in the context of
- the B.1.1.7 lineage and the B.1.1.7-M:V70L sub-lineage, the numbers were even more striking
 (Figure 2). While the percentage of all B.1.1.7 isolates that carried the S:178H mutation
 increased from 0% in January 2021 to 1.8% in April 2021, there was a significant increase from
 0% to 64.8% in B.1.1.7-M:V70L sub-lineage isolates that carried the S:D178H mutation were
 - observed in the same time period. (Figure 2A, Table 2). The B.1.1.7-M:V70L-S:D178H sublineage was exclusive to the U.S. (Table 2), and findings when examined globally were not as
 striking (0% to 0.56% and 0% to 37%, respectively) (Figure 2A, Table 2).
 - 124 The S:D178H mutation was also seen in other lineages including B.1.234 and B.1. In February, it
 - was detected 10 times in 6 states and the first two were reported in California on February 4^{th} ,
 - both within this B.1.1.7 sub-lineage. Overall, 98.93% of the S:D178H carrying viral isolates
 - 127 belonged to this new B.1.1.7 sub-lineage.

Within the U.S., most isolates of this lineage were from Washington, California, and Ohio 128 (Figure 3). California and Washington showed the greatest increases in terms of the percentage 129 of B.1.1.7 isolates carrying the S:D178H mutation. In Washington, the S:D178H mutation was 130 absent until February 2021, where it quickly increased to account for 9.6% (296/3077) of all 131 viral isolates in March and 14.8% (364/2464) in April (Table 3). It accounted for 36.8% 132 (364/990) of the April B.1.1.7 isolates in Washington (Figure 2C, Table 3). In California, 133 S:D178H was first seen in December 2020, but it was not seen within the B.1.1.7 lineage until 134 February 4th, 2021 (Table 3). Its prevalence increased to 1.6% (45/2904) in April compared to 135

all isolates studied in California, and 3.3% (45/1353) of the B.1.1.7 isolates (Figure 2C, Table 3).

138 Origin and transmission of the B.1.1.7-M:V70L-S:D178H sub-lineage

To understand the origin and evolution of this B.1.1.7-M:V70L-S:D178H sub-lineage, we used 139 140 a) all 1,125 S:D178H carrying viral sequences reported across the globe, b) 1,600 subsampled M:V70L carrying viral sequences across the world, and c) the NC 045512 reference genome. 141 These sequences were further filtered with requirements of being at least 27,000 bp and having 142 143 complete date information. 2,609 genomes were kept for final phylogenetic and transmission analysis using Nextstrain, rooted by NC_045512 (Figure 1). The D178H branch divergence date 144 was estimated to be January 23, 2021, with a date confidence interval of January 17, 2021 to 145 February 3, 2021. It likely originated in California (66% probability) or Washington (34% 146 147 probability).

- Estimated transmission routes are demonstrated in **Figure 3**, where the size of the circle represents the number of cases from this sub-lineage in each state, and the line colors correspond to the exporting locations, California, Washington, and Ohio contributed the majority of transmissions compared to other states. This sub-lineage was clearly exclusive to the U.S., and not reported in any other countries at the time of the study.
- not reported in any other countries at the time of the study.

153 Signature mutations of the B.1.1.7-M:V70L-S:D178H sub-lineage

Within this sub-lineage, the most common signature mutations were the same as B.1.1.7 signature mutations, with the additional M:V70L and S:D178H mutations. There were no other novel common spike mutations within this sub-lineage.

157 **Protein structure and mutation effect prediction**

The 3D structure of the Spike protein, as visualized using the CoV3D mutation viewer. Using these results we were able to show that the S:D178H mutation is close structurally to two signature deletions of B.1.1.7, HV69_70del and Y144del (**Figure 4**). They are all surface exposed and likely alter N terminal domain (NTD) tertiary configuration.

162

163 **Discussion**

164

In March 2021, the B.1.1.7-M:V70L-S:D178H lineage appeared abruptly at high prevalence 165 (35.6%) in all reported B.1.1.7 isolates in Washington. This was a remarkable finding as it was 166 absenting in 115 Washington B.1.1.7 isolates reported in February. This abrupt change could 167 reflect undersampling or potentially reflect superspreader events. Given the spike in the number 168 169 of B.1.1.7 cases, this sub-lineage clearly appears to be more transmissible than even the original B.1.1.7 lineage given the spike in the number of B.1.1.7 cases. This finding warrants prompt and 170 further attention by public health authorities, as this mutation profile is closely linked to the 171 resurgence of cases in Washington in particular. It also strongly supports the now widely 172 recognized need for more extensive SARS-CoV-2 viral sequencing of PCR positive COVID-19 173 cases for detection of new mutations of concern as part of widespread genomic surveillance (16, 174 175 17).

177 The S:D178H mutation, while demonstrably associated here with the more pathogenic B.1.1.7 lineage, is not necessarily by itself more pathogenic. Dozens of SARS-CoV-2 genomes that carry 178 the S:D178H mutation were reported before February, but none of these demonstrated the 179 180 increased frequency seen when the mutation occurs in the context of the B.1.1.7 lineage. Phylogenetic analysis revealed a distinct and long branch leading to the new S:D178 branch after 181 M:V70L. Together, these observations suggest that the S:D178H mutation is recurrent, but only 182 increased exponentially in the context of the more pathogenic B.1.1.7 lineage, which serves as an 183 argument for its fitness. This is the same observed with other deleterious mutations like the 184 N501Y and E484K mutations, both of which are now superimposed on distinct and separate 185 more pathogenic lineages. The S:D178H mutation arose independently again in the U.S. on the 186 B.1.1.7-M:V70L background. The rapid increase in its prevalence, only after its acquisition by 187 the B.1.1.7-M:V70L sub-lineage suggests this combination of mutations is associated with 188 189 increased transmissibility. It is also of interest that this mutation occurs in the NTD, unlike most 190 of the mutations associated with current VOC that are centered on the spike protein RBD, implying that NTD mutations beyond the original 69-70del and the 144del are of concern. And 191 192 finally, it should be noted that this NTD mutation co-exists with the previously reported M 193 protein mutation M:V70L, suggesting that M protein mutations also contribute to enhanced 194 biologic 'fitness' or pathogenicity of this sub-lineage.

195

196 The appearance of the S:D178H mutation in the context of the B.1.1.7 lineage is temporally associated with the increased incidence of COVID-19 in Washington. New cases in Washington 197 were higher than the national level at the time of the study. According to New York Time 198 199 COVID-19 dashboard, the 7-day average of new cases on May 2 was 1,379 in Washington, which was only a 50% reduction compared to 2,757 cases on December 15. In comparison, the 200 201 numbers on May 2 was 49,270 in U.S., a 77.3% reduction from the December 15 number of 202 21,7325. The appearance of this new B.1.1.7 sub-lineage temporally linked to increased cases in 203 Washington warrants further investigation.

204

205 The potential effect of the S:D178H mutation on immunity and vaccine 'escape' also warrant further analysis. Mutations in the Spike N-terminal domain have been associated with lack of 206 neutralization by NTD directed antibodies, especially when the N5 loop is affected (18, 19). The 207 208 NTD initiates viral binding to the ACE2 receptor expressing host cell. Since the D178H falls in the NTD domain close to the N5 loop, it may alter NTD structure and antibody recognition. It 209 may thus have a similar immune evasion effect as the HV69-70del and Y144del mutations, or it 210 may further enhance that of the two other mutations, based on the 3D model. These findings 211 highlight the continued importance of active genomic surveillance to monitor the spread of this 212 B.1.1.7-M:V70L-S:178H lineage. 213

214 Acknowledgments

We would like to acknowledge all members of the Department of Pathology and Laboratory Medicine (PLM) at Children's Hospital Los Angeles for dedication towards providing excellent patient care throughout the pandemic, including especially the rapid launch of both the COVID-19 diagnostic test in the Clinical Microbiology and Virology Laboratory and the SARS-CoV-2 whole genome sequencing assay at the Center for Personalized Medicine in March 2020, both with the support of Thermo Fisher and Paragon Genomics, with whom these assays were developed. We would like to acknowledge the frontline healthcare workers who remain devoted

in the fight against COVID-19. We would also like to acknowledge all institutions that have

contributed the SARS-CoV-2 sequences timely, as well as NCBI, GISAID, and Nextstrain for
 providing valuable resources for SARS-CoV-2 genomics.

225 **Disclosure statement**

226 The authors declare no potential conflict of interest.

227 **References:**

- Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, Calum Semple G. SAGE
 meeting report. January 21, 2021.
- 2302. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD.
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect
- recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021 Mar 10;29(3):463476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8. PMID: 33592168; PMCID:
- 234 PMC7869748.
- 2353. Shen L, Maglinte DT, Ostrow D, Pandey U, Bootwalla M, Ryutov A, Govindarajan A, Ruble D,
 236 Han J, Triche TJ, Dien Bard J, Biegel JA, Judkins AR, Gai X. Children's Hospital Los Angeles
- 237 COVID-19 Analysis Research Database (CARD) A Resource for Rapid SARS-CoV-2 Genome
- Identification Using Interactive Online Phylogenetic Tools. bioRxiv 2020.05.11.089763; doi:
 10.1101/2020.05.11.089763
- Shen L, Dien Bard J, Biegel JA, Judkins AR, Gai X. Comprehensive Genome Analysis of 6,000 2404. 241 U.S. SARS-CoV-2 Isolates Reveals Haplotype Signatures and Localized Transmission Patterns Microbiol. 242 State and by Country. Front 2020 Sep 3;11:573430. doi: by
- 243 10.3389/fmicb.2020.573430. PMID: 33013809; PMCID: PMC7509426.
- 2445. Pandey U, Yee R, Shen L, Judkins AR, Bootwalla M, Ryutov A. Maglinte DT, Ostrow D, Precit
- M, Biegel JA, Bender JM, Gai X, Dien Bard J. High prevalence of SARS-CoV-2 genetic
 variation and D614G mutation in pediatric patients with COVID-19. *Open Forum Infectious Diseases*, ofaa551,
- 2486. Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, Aguayo-Hiraldo P, Pinsky
- 249 BA, Pekosz A, Shen L, Boyd SD, Wirz OF, Röltgen K, Bootwalla M, Maglinte DT, Ostrow D,
- 250 Ruble D, Han JH, Biegel JA, Li M, Huang C, Sahoo MK, Pannaraj PS, O'Gorman M, Judkins
- AR, Gai X, Bard JD. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv [Preprint]. 2021 Mar
- 252 and young adults with impared numbral minumty. medicate [Frephilt]. 2021 Wat 253 2:2021.02.27.21252099. doi: 10.1101/2021.02.27.21252099. Update in: EBioMedicine. 2021
- 254 Apr 26;67:103355. PMID: 33688673; PMCID: PMC7941650.
- 2557. Shen L, Bard JD, Triche TJ, Judkins AR, Biegel JA, Gai X. Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and 256 257 therapeutic implications. Emerg Microbes Infect. 2021 Apr 26:1-24. doi: 258 10.1080/22221751.2021.1922097. Epub ahead of print. PMID: 33896413.
- 2598. Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, Aguayo-Hiraldo P, Pinsky
- 260 BA, Pekosz A, Shen L, Boyd SD, Wirz OF, Röltgen K, Bootwalla M, Maglinte DT, Ostrow D,
- 261 Ruble D, Han JH, Biegel JA, Li M, Huang C, Sahoo MK, Pannaraj PS, O'Gorman M, Judkins
- 262 AR, Gai X, Dien Bard J. Increased viral variants in children and young adults with impaired

- 263 humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series.
- EBioMedicine. 2021 Apr 26;67:103355. doi: 10.1016/j.ebiom.2021.103355. Epub ahead of print.
 PMID: 33915337; PMCID: PMC8072072.
- 2669. Ryutov A, Gai X, Ostrow D, Maglinte DT, Flores J, Salas EJ, Glucoft M, Smit M, Dien Bard J.
- 267 Utility of viral whole genome sequencing for institutional infection surveillance during the
- 268 SARS-CoV-2 pandemic. Infect Control Hosp Epidemiol. 2021 Apr 19:1-12. doi:
- 269 10.1017/ice.2021.185. Epub ahead of print. PMID: 33866984.
- 27010. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to
 global health. Glob Chall. 2017 Jan 10;1(1):33-46. doi: 10.1002/gch2.1018. PMID: 31565258;
 PMCID: PMC6607375.
- 27311. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to
 reality. Euro Surveill. 2017 Mar 30;22(13):30494. doi: 10.2807/15607917.ES.2017.22.13.30494. PMID: 28382917; PMCID: PMC5388101.
- 27612. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence
- alignment based on fast Fourier transform. Nucleic Acids Res. 2002 Jul 15;30(14):3059-66. doi:
- 278 10.1093/nar/gkf436. PMID: 12136088; PMCID: PMC135756.
- 27913. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear
- 280 R. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
- 281 Era. Mol Biol Evol. 2020 May 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015. Erratum in:
- 282 Mol Biol Evol. 2020 Aug 1;37(8):2461. PMID: 32011700; PMCID: PMC7182206.
- 28314. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis.
 Virus Evol. 2018 Jan 8;4(1):vex042. doi: 10.1093/ve/vex042. PMID: 29340210; PMCID: PMC5758920.
- 28615. Ittisoponpisan S, Islam SA, Khanna T, Alhuzimi E, David A, Sternberg MJE. Can Predicted
- 287 Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease
- 288 Associated? J Mol Biol. 2019 May 17;431(11):2197-2212. doi: 10.1016/j.jmb.2019.04.009.
- 289 Epub 2019 Apr 14. PMID: 30995449; PMCID: PMC6544567. [Google Scholar]
- 29016. Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature. 2021
 Jan;589(7842):337-338. doi: 10.1038/d41586-021-00065-4. PMID: 33452508.
- 29217. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States-
- Challenges and Opportunities. JAMA. 2021 Feb 17. doi: 10.1001/jama.2021.2294. Epub aheadof print. PMID: 33595644
- 29518. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD,
- 296 Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng
- Z, Huang Y, Ho DD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature.
- 298 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8. PMID: 33684923.
- 30019. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE,
- de Oliveira T, Vermeulen M, van der Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring
- 302 S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes
- neutralization by South African COVID-19 donor plasma. Nat Med. 2021 Apr;27(4):622-625.
- doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2. PMID: 33654292.
- 305

Figure 1. Branching off a sub-lineage of B.1.1.7 that is distinguished by the M:V40L mutation because of the emergence of the S:D178H mutation on January 23rd, 2021 as estimated. Each dot represents an isolate and is colored according to the state where it was reported. The inset provides more information about the branching S:D178H mutation, namely the genomic position, the inferred date, the data confidence interval, and the likely states of origin.

313



318 Figure 2. Prevalence of the B.1.1.7 sub-lineage carrying mutation S:D178H Globally, U.S.,

Washington, and California. A. Percentages of B.1.1.7 (blue) or B.1.1.7-M:V70L (orange)

isolates that carried the S:D178H mutation from January to April 2021 in U.S. and globally,

321 respectively. B. Percentages of B.1.1.7 isolates that carried the S:D178H mutation from

- 322 September 2020 to April 2021 in California. C. Percentages of B.1.1.7 isolates that carried the
- 323 S:D178H mutation from January 2021 to April 2021 in Washington.



B. %B.1.1.7 with S:D178H in California



C. %B.1.1.7 with S:D178H in Washington



Figure 3. Transmission of the 1026 B.1.1.7-MV70L-S:D178H isolates across the U.S..

The size of the circles are drawn proportional to the number of cases in the specific state.Lines are colored the same as the exporting states.



331 332

Figure 4. Structural location of the D178H and other spike protein mutations in the B.1.1.7

- **lineage.** D178H is in close proximity to other amino acids in the NTD that are affected in the D1177H $\frac{1}{1000}$ $\frac{1}$
- 335 B.1.1.7 lineage, HV69-70del and Y144/Y145del (top right).



337

336

340

Table 1. Number of isolates from the B.1.1.7 lineage and with the M:V70L mutation in the U.S. and globally

Month	Country	All isolates	B.1.1.7 isolates	All isolates w/ M:V70L	B.1.1.7 isolates w/ M:V70L	% all isolates w/ M:V70L	% B.1.1.7 isolates w/ M:V70L	% M:V70L in B.1.1.7
2021- 04	U.S.	44878	25837	720	716	1.60	2.77	99.44
2021- 03	U.S.	91468	36034	965	953	1.06	2.64	98.76
2021- 02	U.S.	56669	6859	309	287	0.55	4.18	92.88
2021- 01	U.S.	52532	1365	193	150	0.37	10.99	77.72
2020- 12	U.S.	23593	117	46	43	0.50	36.75	93.48
2020- 11	U.S.	17878	2	4	1	0.02	50.00	25
2021- 04	World	109886	82392	1257	1253	1.14	1.52	99.68
2021- 03	World	291238	195853	2607	2592	0.90	1.32	99.42
2021- 02	World	219853	107841	1845	1816	0.84	1.68	98.43
2021- 01	World	195282	69514	1005	932	0.51	1.34	92.74
2020- 12	World	107503	18356	257	236	0.24	1.29	91.83
2020- 11	World	81587	2222	39	29	0.05	1.31	74.36

343

Table 2. Number of isolates form the B.1.1.7 lineage and with the S:D178H mutation in the U.S. and globally

Aonth	Coun try	All isolates	B.1.1.7 isolates	All isolates w/ S: D178H	B.1.1.7 isolates w/ S:D178H	% all isolates w/ S: D178H	%B.1.1.7 isolates w/ S:D178H	% S:D178H from B.1.1.7 isolates
021-04	U.S.	44878	25837	469	464	1.05	1.80	98.93
021-03	U.S.	91468	36034	402	399	0.44	1.11	99.25
021-02	U.S.	56669	6859	18	10	0.03	0.15	55.56
021-01	U.S.	52532	1365	5	0	0.01	0.00	0.00
021-04	World	109886	82392	469	464	0.43	0.56	98.93
021-03	World	291238	195853	403	400	0.14	0.20	99.26
021-02	World	219853	107841	20	11	0.01	0.01	55.00
021-01	World	195282	69514	7	0	7	0.00	0.00

352 Table 3. Number of isolates from the B.1.1.7 lineage and with the S:D178H mutation in the

353 states of California and Washington

State	Month	All isolates	B.1.1.7 isolates	Isolates w/ S:D178H	% of all isolates w/ S:D178H	% B.1.1.7 isolates w/ S:D178H
California	2021-04	2904	1353	45	1.55	3.33%
California	2021-03	9951	2254	46	0.46	2.04%
California	2021-02	8889	589	10	0.11	0.68%
California	2021-01	10441	214	4	0.04	0%
Washington	2021-04	2464	990	364	14.77	36.8%
Washington	2021-03	3077	832	296	9.62	35.6%
Washington	2021-02	2152	115	0	0.0	0%
Washington	2021-01	1510	33	0	0.0	0%

354